High level cephalosporin-resistant Enterobacteriaceae ventilator-associated pneumonia: Prognostic factors based on a cohort study

Journal of Hospital Infection

Volumn 77, Issue 1, 2011, Pages 64-69

  Aubron, C ^a   Chaari, A ^a   Bronchard, R ^a   Armand Lefevre L ^a   Montravers, P ^a   Regnier B ^a   Wolff, M ^a   Lucet, J C ^a  

^a BICHAT HOSPITAL   (France)

Author keywords

Cephalosporin resistance; Enterobacteriaceae; Ventilator associated pneumonia

Indexed keywords

AMIKACIN; AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; BETA LACTAMASE AMPC; CEFEPIME; CEFOTAXIME; CEFOXITIN; CEFTAZIDIME; CEPHALOSPORIN; CIPROFLOXACIN; COTRIMOXAZOLE; GENTAMICIN; IMIPENEM; NALIDIXIC ACID; OFLOXACIN; TICARCILLIN;

ADULT; AGED; ANTIBIOTIC RESISTANCE; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DEMOGRAPHY; DISEASE SEVERITY; ENTEROBACTERIACEAE; FEMALE; HOSPITAL ADMISSION; HUMAN; INFECTION SENSITIVITY; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MALE; MULTIPLE ORGAN FAILURE; PROGNOSIS; RETROSPECTIVE STUDY; VENTILATOR ASSOCIATED PNEUMONIA;

AGED; ANTI-BACTERIAL AGENTS; BETA-LACTAM RESISTANCE; CEPHALOSPORINS; COHORT STUDIES; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTIONS; FEMALE; HUMANS; INTENSIVE CARE UNITS; MALE; MIDDLE AGED; PNEUMONIA, VENTILATOR-ASSOCIATED; PROGNOSIS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SHOCK;

EID: 78650514309     PISSN: 01956701     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhin.2010.09.010     Document Type: Article

References (34)

1. Kaneko K., Okamoto R., Nakano R., et al. Gene mutations responsible for overexpression of AmpC beta-lactamase in some clinical isolates of Enterobacter cloacae. J Clin Microbiol 2005, 43:2955-2958.
2. Schwaber M.J., Graham C.S., Sands B.E., et al. Treatment with a broad-spectrum cephalosporin versus piperacillin-tazobactam and the risk for isolation of broad-spectrum cephalosporin-resistant Enterobacter species. Antimicrob Agents Chemother 2003, 47:1882-1886.
3. Yang Y.J., Livermore D.M. Chromosomal beta-lactamase expression and resistance to beta-lactam antibiotics in Proteus vulgaris and Morganella morganii. Antimicrob Agents Chemother 1988, 32:1385-1391.
4. Walder M., Haeggman S., Tullus K., Burman L.G. A hospital outbreak of high-level beta-lactam-resistant Enterobacter spp.: association more with ampicillin and cephalosporin therapy than with nosocomial transmission. Scand J Infect Dis 1996, 28:293-296.
5. Lee S.O., Kim Y.S., Kim B.N., et al. Impact of previous use of antibiotics on development of resistance to extended-spectrum cephalosporins in patients with Enterobacter bacteremia. Eur J Clin Microbiol Infect Dis 2002, 21:577-581.
6. Kaye K.S., Cosgrove S., Harris A., et al. Risk factors for emergence of resistance to broad-spectrum cephalosporins among Enterobacter spp. Antimicrob Agents Chemother 2001, 45:2628-2630.
7. Nicolle L.E. Prior antimicrobial therapy and resistance of Enterobacter, Citrobacter and Serratia to third generation cephalosporins. J Hosp Infect 1988, 11:321-327.
8. D'Agata E., Venkataraman L., DeGirolami P., Samore M. Molecular epidemiology of acquisition of ceftazidime-resistant Gram-negative bacilli in a nonoutbreak setting. J Clin Microbiol 1997, 35:2602-2605.
9. Jacobson K.L., Cohen S.H., Inciardi J.F., et al. The relationship between antecedent antibiotic use and resistance to extended-spectrum cephalosporins in group I beta-lactamase-producing organisms. Clin Infect Dis 1995, 21:1107-1113.
10. Kang C.I., Kim S.H., Park W.B., et al. Bloodstream infections caused by antibiotic-resistant Gram-negative bacilli: risk factors for mortality and impact of inappropriate initial antimicrobial therapy on outcome. Antimicrob Agents Chemother 2005, 49:760-766.
11. Chow J.W., Fine M.J., Shlaes D.M., et al. Enterobacter bacteremia: clinical features and emergence of antibiotic resistance during therapy. Ann Intern Med 1991, 115:585-590.
12. Cosgrove S.E., Kaye K.S., Eliopoulous G.M., Carmeli Y. Health and economic outcomes of the emergence of third-generation cephalosporin resistance in Enterobacter species. Arch Intern Med 2002, 162:185-190.
13. Chastre J., Fagon J.Y. Ventilator-associated pneumonia. Am J Respir Crit Care Med 2002, 165:867-903.
14. Trouillet J.L., Vuagnat A., Combes A., et al. Pseudomonas aeruginosa ventilator-associated pneumonia: comparison of episodes due to piperacillin-resistant versus piperacillin-susceptible organisms. Clin Infect Dis 2002, 34:1047-1054.
15. Combes A., Luyt C.E., Trouillet J.L. Impact of antibiotic-resistant bacteria on the outcome of ventilator-associated pneumonia. Semin Respir Crit Care Med 2006, 27:23-28.
16. Blot S., Vandewoude K., De Bacquer D., Colardyn F. Nosocomial bacteremia caused by antibiotic-resistant Gram-negative bacteria in critically ill patients: clinical outcome and length of hospitalization. Clin Infect Dis 2002, 34:1600-1606.
17. De Champs C., Poirel L., Bonnet R., et al. Prospective survey of beta-lactamases produced by ceftazidime-resistant Pseudomonas aeruginosa isolated in a French hospital in 2000. Antimicrob Agents Chemother 2002, 46:3031-3034.
18. Jarlier V., Nicolas M.H., Fournier G., Philippon A. Extended broad-spectrum beta-lactamases conferring transferable resistance to newer beta-lactam agents in Enterobacteriaceae: hospital prevalence and susceptibility patterns. Rev Infect Dis 1988, 10:867-878.
19. Chastre J., Wolff M., Fagon J.Y., et al. Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial. JAMA 2003, 290:2588-2598.
20. McCabe W.R., Jackson G.G. Gram-negative bacteremia. Arch Intern Med 1962, 110:847-864.
21. Le Gall J.R., Lemeshow S., Saulnier F. A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter study. JAMA 1993, 270:2957-2963.
22. Vincent J.L., Moreno R., Takala J., et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med 1996, 22:707-710.
23. Fagon J.Y., Chastre J., Vuagnat A., et al. Nosocomial pneumonia and mortality among patients in intensive care units. JAMA 1996, 275:866-869.
24. Kollef M.H., Sherman G., Ward S., Fraser V.J. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest 1999, 115:462-474.
25. American Thoracic Society A consensus statement. Hospital-acquired pneumonia in adults: diagnosis, assessment of severity, initial antimicrobial therapy, and preventive strategies. Am J Respir Crit Care Med 1996, 153:1711-1725.
26. National Nosocomial Infections Surveillance (NNIS) System report, data summary from January 1990-May 1999, issued June 1999. Am J Infect Control 1999, 27:520-532.
27. Blot S.I., Vandewoude K.H., Colardyn F.A. Evaluation of outcome in critically ill patients with nosocomial Enterobacter bacteremia: results of a matched cohort study. Chest 2003, 123:1208-1213.
28. Meehan T.P., Fine M.J., Krumholz H.M., et al. Quality of care, process, and outcomes in elderly patients with pneumonia. JAMA 1997, 278:2080-2084.
29. Kumar A., Roberts D., Wood K.E., et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006, 34:1589-1596.
30. Iregui M., Ward S., Sherman G., et al. Clinical importance of delays in the initiation of appropriate antibiotic treatment for ventilator-associated pneumonia. Chest 2002, 122:262-268.
31. Cosgrove S.E. The relationship between antimicrobial resistance and patient outcomes: mortality, length of hospital stay, and health care costs. Clin Infect Dis 2006, 42(Suppl. 2):S82-89.
32. Giske C.G., Monnet D.L., Cars O., et al. Clinical and economic impact of common multidrug-resistant gram-negative bacilli. Antimicrob Agents Chemother 2008, 52:813-821.
33. Combes A., Luyt C.E., Fagon J.Y., et al. Impact of piperacillin resistance on the outcome of Pseudomonas ventilator-associated pneumonia. Intensive Care Med 2006, 32:1970-1978.
34. Meybeck A., Ricard J.D., Barnaud G., et al. Incidence and impact on clinical outcome of infections with piperacillin/tazobactam resistant Escherichia coli in ICU: a retrospective study. BMC Infect Dis 2008, 8:67.